新型夹心免疫法测定总睾酮的分析性能与临床分类价值
该研究以LC-MS/MS为参考方法,比较Mindray TESTO与Siemens TSTII免疫法测定387例残余血清样本(226例睾酮<1.0 ng/mL)及119例血液透析样本(94例男性)中的总睾酮。Mindray TESTO总CV为1.68-2.71%,低浓度样本与LC-MS/MS相关性更高(r=0.9603 vs 0.8920),在育龄女性生化高雄激素分类中灵敏度更高(88.89% vs 11.11%),在男性透析患者生化睾酮缺乏分类中准确度更高(94.68% vs 88.30%)。
要点
- Mindray TESTO在低浓度睾酮样本与LC-MS/MS一致性优于Siemens TSTII。
- 育龄女性生化高雄激素分类灵敏度88.89%,κ=0.784。
- 男性透析患者生化睾酮缺乏分类准确度94.68%,κ=0.838。
核心结论
- 新型夹心免疫法在低睾酮浓度下与LC-MS/MS一致性改善。
- 该法在生化睾酮升高与缺乏的临床分类中表现良好。
研究设计与样本
- 以LC-MS/MS为参考方法比较两种免疫法。
- 387例残余临床血清样本,其中226例睾酮<1.0 ng/mL。
- 133例育龄女性评估生化高雄激素分类。
- 119例血液透析样本(94例男性,25例女性),94例男性评估生化睾酮缺乏分类。
- 分析包括Passing-Bablok回归、Bland-Altman分析及独立精密度、线性、干扰研究。
主要发现
- Mindray TESTO总CV为1.68-2.71%,线性良好(r=0.9997)。
- 交叉反应普遍较低,但保泰松产生超过±10%的偏倚。
- 两种免疫法与LC-MS/MS均强相关,Mindray TESTO在低浓度样本相关性更高(r=0.9603 vs 0.8920)且一致性界限更窄。
- 育龄女性生化高雄激素分类:Mindray TESTO灵敏度88.89% vs 11.11%,κ=0.784 vs 0.189。
- 男性透析患者生化睾酮缺乏分类:Mindray TESTO准确度94.68% vs 88.30%,κ=0.838 vs 0.680;ROC AUC无显著差异(0.966 vs 0.956;p=0.2776)。
关键数值与推荐
- 低浓度样本相关性Mindray TESTO r=0.9603,Siemens TSTII r=0.8920。
- 育龄女性高雄激素分类灵敏度88.89% vs 11.11%,κ=0.784 vs 0.189。
- 男性透析患者睾酮缺乏分类准确度94.68% vs 88.30%,κ=0.838 vs 0.680。
- ROC AUC 0.966 vs 0.956,p=0.2776。
临床怎么用
- 在低睾酮浓度及透析人群中可考虑使用该新型夹心免疫法。
- 对育龄女性生化高雄激素及男性透析患者睾酮缺乏的分类具有较高灵敏度与准确度。
- 需注意保泰松可导致超过±10%的偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the analytical performance and clinical classification value of a novel sandwich testosterone immunoassay, particularly for biochemical testosterone elevation in women and deficiency in male hemodialysis patients, using LC-MS/MS as the reference method. METHODS: A total of 387 residual clinical serum samples were compared using Mindray TESTO, Siemens TSTII, and liquid chromatography-tandem mass spectrometry (LC-MS/MS). Among these, 226 had testosterone concentrations <1.0 ng/mL, and 133 reproductive-age women were evaluated for biochemical hyperandrogenism classification. An additional 119 hemodialysis samples (94 men, 25 women) were assessed, with the 94 men evaluated for biochemical testosterone deficiency classification. Analyses included Passing-Bablok regression, Bland-Altman analysis, and independent imprecision, linearity, and interference studies. RESULTS: The Mindray TESTO assay showed total CVs of 1.68-2.71 % and good linearity (r=0.9997). Cross-reactivity was generally low, although phenylbutazone produced biases exceeding ±10 %. Both immunoassays correlated strongly with LC-MS/MS, with Mindray TESTO showing higher correlation and narrower limits of agreement in low-concentration samples (r=0.9603 vs. 0.8920). In women of reproductive age, Mindray TESTO demonstrated higher sensitivity (88.89 vs. 11.11 %) and κ agreement (0.784 vs. 0.189) for biochemical hyperandrogenism classification. In male hemodialysis patients, it achieved higher accuracy (94.68 vs. 88.30 %) and κ agreement (0.838 vs. 0.680) for biochemical testosterone deficiency classification. The ROC AUCs did not differ significantly (0.966 vs. 0.956; p=0.2776). CONCLUSIONS: The novel sandwich immunoassay showed improved agreement with LC-MS/MS at low testosterone concentrations and favorable performance in classifying biochemical testosterone elevation and deficiency.
引用
- Shi H, Wei H, Han S, et al. Analytical performance and clinical classification value of a novel sandwich immunoassay for total testosterone measurement in low-concentration and hemodialysis populations. Clin Chem Lab Med. 2026. PMID: 42849045. doi:10.1515/cclm-2026-0886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。